GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Total Operating Expense

Paradigm Biopharmaceuticals (ASX:PAR) Total Operating Expense : A$77.25 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Total Operating Expense?

Paradigm Biopharmaceuticals's Total Operating Expense for the six months ended in Dec. 2023 was A$50.30 Mil. Paradigm Biopharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$77.25 Mil.

Paradigm Biopharmaceuticals Total Operating Expense Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Total Operating Expense Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Operating Expense
Get a 7-Day Free Trial 10.22 17.17 43.31 47.93 60.07

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.75 20.18 33.12 26.95 50.30

Paradigm Biopharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$77.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Total Operating Expense
Comparable Companies
ASX:BOT ASX:RAC ASX:OPT ASX:PYC ASX:PIQ ASX:RCE ASX:BIT ASX:CU6 ASX:ALA ASX:DXB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PBIGF:USA
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Website
https://www.paradigmbiopharma.com
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).